Drug Profile
Research programme: respiratory disorder therapeutics - Signum Biosciences
Alternative Names: SIG-0980Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Signum Biosciences
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)
- 13 Oct 2010 Preclinical development is ongoing in USA